Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BYV9
UPID:
BACH2_HUMAN
Alternative names:
BTB and CNC homolog 2
Alternative UPACC:
Q9BYV9; E1P518; Q59H70; Q5T793; Q9NTS5
Background:
Transcription regulator protein BACH2, also known as BTB and CNC homolog 2, plays a pivotal role in cellular processes, including transcription regulation, apoptosis in response to oxidative stress, and nuclear import of actin. It binds to Maf recognition elements, coordinating transcription activation and repression by MAFK, and is crucial for adaptive immunity, regulatory T-cell function, and B-cell maturation.
Therapeutic significance:
BACH2's involvement in Immunodeficiency 60 and autoimmunity, a disorder characterized by intestinal inflammation, recurrent infections, and impaired lymphocyte maturation, highlights its potential as a target for therapeutic intervention. Understanding the role of BACH2 could open doors to potential therapeutic strategies.